← Back to home

LIVER CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, GASTRIC ADENOCARCINOMA, CERVICAL CANCER, MSI-H COLORECTAL CANCER

Clinical trials for LIVER CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, GASTRIC ADENOCARCINOMA, CERVICAL CANCER, MSI-H COLORECTAL CANCER explained in plain language.

Never miss a new study

Get alerted when new LIVER CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, GASTRIC ADENOCARCINOMA, CERVICAL CANCER, MSI-H COLORECTAL CANCER trials appear

Sign up with your email to follow new studies for LIVER CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, GASTRIC ADENOCARCINOMA, CERVICAL CANCER, MSI-H COLORECTAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

New drug combo tested for Tough-to-Treat cancers

Disease control Terminated

This early-stage study tested the safety of combining two experimental drugs, JS004 and toripalimab, in patients with advanced solid tumors like liver, stomach, and cervical cancer who had not responded to standard treatments. The main goal was to see if the combination was safe …

Matched conditions: LIVER CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, GASTRIC ADENOCARCINOMA, CERVICAL CANCER, MSI-H COLORECTAL CANCER

Phase: PHASE1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control

Last updated Apr 02, 2026 06:11 UTC

LIVER CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, GASTRIC ADENOCARCINOMA, CERVICAL CANCER, MSI-H COLORECTAL CANCER

Get alerted when new LIVER CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, GASTRIC ADENOCARCINOMA, CERVICAL CANCER, MSI-H COLORECTAL CANCER trials appear

New drug combo tested for Tough-to-Treat cancers